Javier Cotignola

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma
    Javier Cotignola
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 8:10. 2007
  2. ncbi Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression
    Javier Cotignola
    Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Negat Results Biomed 6:9. 2007
  3. ncbi Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma
    Javier Cotignola
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Invest Dermatol 132:1471-8. 2012
  4. ncbi Evaluation of the clonal origin of multiple primary melanomas using molecular profiling
    Irene Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Invest Dermatol 129:1972-82. 2009
  5. ncbi CDKN2A germline mutations in individuals with cutaneous malignant melanoma
    Irene Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Invest Dermatol 127:1234-43. 2007
  6. ncbi NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH
    Irene Szijan
    Genetica y Biologia Molecular, Facultad de Farmacia y Bioquimica y Hospital de Clinicas, Universitdad de Buenos Aires, Junin 956, 1113 Buenos Aires, Argentina
    Neuromolecular Med 3:41-52. 2003
  7. ncbi Direct deletion analysis in two Duchenne muscular dystrophy symptomatic females using polymorphic dinucleotide (CA)n loci within the dystrophin gene
    Florencia Giliberto
    Catedra de Genetica y Biologia Molecular, Facultad de Famacia y Bioquimica, University of Buenos Aires, and Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
    J Biochem Mol Biol 36:179-84. 2003

Detail Information

Publications7

  1. ncbi Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma
    Javier Cotignola
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 8:10. 2007
    ..Some polymorphisms are known to influence gene expression, protein activity, stability, and interactions, and they were shown to be associated with certain tumor phenotypes and cancer risk...
  2. ncbi Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression
    Javier Cotignola
    Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Negat Results Biomed 6:9. 2007
    ..Functional polymorphisms in MMP genes' promoter regions may modulate the risk for melanoma progression...
  3. ncbi Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma
    Javier Cotignola
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Invest Dermatol 132:1471-8. 2012
    ..Further studies are needed to determine whether a nearby functional polymorphism is responsible for this effect in premenopausal women...
  4. ncbi Evaluation of the clonal origin of multiple primary melanomas using molecular profiling
    Irene Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Invest Dermatol 129:1972-82. 2009
    ....
  5. ncbi CDKN2A germline mutations in individuals with cutaneous malignant melanoma
    Irene Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Invest Dermatol 127:1234-43. 2007
    ..With the exception of the variant in position -34 of CDKN2A of known functional consequence, the remaining rare variants in the non-coding region have no apparent impact on risk...
  6. ncbi NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH
    Irene Szijan
    Genetica y Biologia Molecular, Facultad de Farmacia y Bioquimica y Hospital de Clinicas, Universitdad de Buenos Aires, Junin 956, 1113 Buenos Aires, Argentina
    Neuromolecular Med 3:41-52. 2003
    ..Denaturing HPLC analysis of small mutations and microarray-CGH of large deletions are complementary, fast, and efficient methods for the detection of mutations in tumor tissues...
  7. ncbi Direct deletion analysis in two Duchenne muscular dystrophy symptomatic females using polymorphic dinucleotide (CA)n loci within the dystrophin gene
    Florencia Giliberto
    Catedra de Genetica y Biologia Molecular, Facultad de Famacia y Bioquimica, University of Buenos Aires, and Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
    J Biochem Mol Biol 36:179-84. 2003
    ..The use of microsatellite genotyping within the DMD gene enables the detection of the mutant allele in female carriers. It is also a useful method to provide DMD families with more accurate genetic counseling...